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Purpose: To: 1) assess the correlation between CT vascularity and a candidate molecular marker of RCC
metastasis (insulin-like mRNA binding protein-3 (IMP3)); and 2) demonstrate the differential expression
of IMP3 in high vs. low vascular tumors.
Experimental design: Retrospectively obtained contrast CT from 72 patients with primary RCC were used
to establish threshold values for Low, Intermediate and High tumor vascularity. Paired histopathology
specimens from 33 of these patients were used for immunohistochemistry (IHC) to correlate CT with
IMP-3 expression. IMP-3 gene expression studies were performed on RCC and poorly vascular prostate
cancer (PC) human bone metastases samples to conﬁrm presence of IMP3 in metastatic samples from
RCC. Gene expression studies were performed on RCC 786-O and PC3 cell lines to conﬁrm the presence of
high expression of IMP3 in the RCC cell line.
Results: IMP-3 expression positively correlated with CT vascular enhancement (po0.01). IMP3 expres-
sion by IHC was strongly positive in all RCC, but weak in PC bone metastases. Real time RT-PCR de-
monstrated a signiﬁcant 4-fold increase in imp-3 expression in RCC 786-O vs. PC3 cells in vitro
(po0.001).
Conclusion: Quantitation of pre-operative CT is a feasible method to phenotype primary RCC vascularity,
which correlates with IMP-3 expression. In situ and cell line studies demonstrate an association between
high IMP-3 expression and RCC bone metastasis. Studies aimed at deﬁning the diagnostic potential of
biomarkers for RCC bone metastasis, and functional signiﬁcance of IMP-3 in RCC vascularity and tumor
progression are warranted.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).GmbH. This is an open access art
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.1. Introduction
There is an estimated 330,000 new cases of renal cell carcino-
ma (RCC) diagnosed each year worldwide, with over 100,000
deaths, and a rising incidence of 3% per year [1]. Although several
advances in the treatment of metastatic RCC have occurred in the
last decade, this disease remains one of the most deadly cancers
with a 5-year survival rate of ∼10% [2–4]. The primary treatment
for localized RCC is surgical resection alone. Although systemic
therapies in the form of receptor tyrosine kinase (RTK) inhibitors
and targets of the mTOR protein have improved length of survival
for patients found to have advanced metastatic disease, there is aicle under the CC BY-NC-ND license
Fig. 1. Assessment of primary tumor vascularity via CT scan in patients with malignant renal cancer. Contrast CT scan was performed on all patients in the study to assess the
vascularity of their primary renal cancer (white dashed line). In the initial analysis, patients with low vascular tumor, as illustrated in images (A) and (B); versus patients with
highly vascular tumors that went on to receive digital subtraction angiography (C–E). Shown are representative: (A) pre-contrast, and (B) early arterial phase images
demonstrating the initial enhancement and uptake of contrast dye (Iohexol 300 mgl/ml) at 30 s of a patient with a low vascular tumor. (C) CT scan of late phase vascular
uptake showing high contrast uptake in the highly vascular tumor, which warranted the subsequent DSA. The patient's DSA conﬁrmed the presence of a major tumor feeding
vessel as seen from image obtained immediately after injection (D; 1–2 s) and late phase (E; 10 s).
C. Xie et al. / Journal of Bone Oncology 4 (2015) 69–7670reluctance to start these treatments with signiﬁcant side effects in
patients with only localized disease [5,6], as many patients will not
go on to develop metastatic disease if treated with surgery alone.
Two important trends in RCC have been noted in the past decade.
The ﬁrst is that the incidence of localized disease has been in-
creasing, despite a plateau in the number of abdominal CT scans
performed that would normally detect such disease [7]. Secondly,
the mortality rate for patients with localized disease has also in-
creased. This is in the setting of no improvements in incidence or
mortality rates for patients with advanced disease [7]. Despite our
best efforts to detect and surgically treat early stage RCC, ap-
proximately 30% of patients will go on to develop advanced me-
tastatic disease [1]. An area in which major improvements could
be made is diagnostic radiology for those patients with localized
disease and a high risk of developing metastases, as early-ag-
gressive treatments could then be justiﬁed. To this end, we aim to
identify novel-clinically relevant radiologic and molecular bio-
markers that can differentiate the metastatic potential of RCC in
patients with local disease. This may alter surveillance and pos-
sibly the indications for starting systemic treatment.
Our research in this area has been focused on understanding
the highly vascular nature of RCC, which has been largely attrib-
uted to loss of function of the von Hippel-Lindau (VHL) gene and
resultant vascular endothelial growth factor (VEGF) over-expres-
sion, as it is an early event during tumorgenesis and is the most
common cause for inherited RCC [8–10]. However, therapies that
speciﬁcally target VEGF and its receptor have failed to demonstrate
signiﬁcant efﬁcacy in clinical trials [11,12]. Moreover, our ob-
servations in a murine xenograft model of bone metastasis de-
monstrated that the major difference between a highly vascular
RCC cell line (786-O) and a prototypical avascular prostate cancer
cell line (PC3) is the presence of large smooth muscle and pericyte
lined blood vessels within the tumor [13], suggests that non-VEGF
signaling pathways may be more important. To test this hypoth-
esis, we performed a microarray analysis of 786-O vs. PC3 by using
Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (ChipLot# LE23BK05) and whole data set has been documented at NCBI
GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token¼qn-
grecewnbothcv&acc¼GSE61942) and a summary of the notable
ﬁndings is presented in Supplementary Table 1.
Based on our search criteria for candidate molecular markers of
RCC vascularity, we chose to focus on insulin-like growth factor II
(IGF-II) mRNA binding protein 3 (IGF2BP3 or IMP3). IMP3 is an
oncofetal mRNA-binding protein and has been recently described
as an independent prognostic marker for renal cell carcinoma
(RCC) distant metastasis, and is associated with shorter survival
[14]. It also has been noted in other cancers to be associated with
cell motility and trans-endothelial migration [15]. IMP3 is a
member of the highly conserved family of proteins that have been
found to be associated with mRNA transport, translation and
turnover. Functionally, IMPs have been shown to modulate cell
proliferation, adhesion, migration and invasion [16]. IMP3 ex-
pression is almost exclusively limited to embryonic development,
as its expression in most adult tissues is undetectable. However, it
has recently been found to have signiﬁcant expression in malig-
nant adult tissue, including RCC [17]. Although an association be-
tween the expression of IMP3 in RCC and prognosis has recently
been discovered, the predictive studies of IMP3 in clinical practice
have not been evaluated [17]. More speciﬁcally, the relationship
between IMP3 expression and pre-operative imaging character-
istics (i.e. computed tomography (CT), magnetic resonance image
(MRI) or digital subtraction angiographic (DSA)) has yet to be in-
vestigated. To address this, we evaluated the relationship between
IMP3 expression in primary RCC versus tumor vascularity quan-
tiﬁed from the pre-operative intravenous contrast CT scan. We also
evaluated the expression of IMP3 via IHC from samples of bone
biopsies obtained from patients with metastatic RCC to bone and
compared them to patients with metastatic prostate bone disease.
The goals of this study were to determine whether vascularity as
assesses by contrast CT is correlated to IMP3 expression and if
IMP3 expression in tumor samples could be used to stratify me-
tastatic disease risk assessment in RCC patients. These ﬁndings
Fig. 2. Semiquantitative scoring systems to assess primary renal cancer vascularity via CT and IMP3 expression by immunohistochemistry (IHC). CT scans were obtained
from the patients prior to their cancer surgery, and the resected tumor was harvested and processed for IHC with antibodies speciﬁc for IMP3. Representative early arterial
phase images (A–C), with corresponding IMP3 IHC micrographs obtained at 200X (D–F) are presented to illustrate the semiquantitative scoring system used to correlate
tumor vascularity with IMP3 expression as follows. Tumor vascularity, based on total Hounsﬁeld Units (HU) of the segmented tumor (red line), was scored as: (A) Low (o20
HU); (B) Intermediate (20–40 HU); or (C) High (440 HU). The intensity of IMP3 IHC staining (brown) was scored as: (D) Weak þ; (E) Moderate þþ; or (F) Strong þþþ as
we have previously described (23). Note that the vascularity of the CT closely correlates with IHC staining for IMP3
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therapy, which is currently not the standard of care for most pa-
tients identiﬁed with RCC.2. Materials and methods
2.1. Patient selection
The institutional research review boards at Zunyi Medical
University and University of Rochester Medical Center approved
this study. This was a retrospective study that (a) did not require
participants to provide written or verbal informed consent to
participate in this study as all (b) participants personal informa-
tion were removed from data collection and (c) both IRBs from
Zunyi Medical University and University of Rochester Medical
Center approved the study design. A retrospective analysis was
conducted of a consecutive series of 72 primary RCC patients who
had histopathologic conﬁrmation of RCC, and who were diagnosed
and treated at the First Afﬁliated Hospital of Zunyi MedicalUniversity (ZMU) and Zunyi Hospital between March 2003 and
January 2010. All 72 patients had undergone pre-operative radio-
graphic analysis with computed tomography (Siemens Somatom
Sensation 16, Germany). Of the 72 initial patients with localized
RCC who underwent CT analysis, 33 patients had parafﬁn blocks
available for performing additional H&E staining and im-
munohistochemistry (IHC) for IMP3. Parafﬁn blocks were not
available for the remaining 39 patients, and therefore IMP3 ana-
lysis was not performed on those tumors. Patients found to have
markedly avid contrast uptake on CT, underwent digital subtrac-
tion angiography (DSA) and embolization. Seven of the 33 patients
with IHC analysis underwent this treatment plan, and therefore
had DSA imaging available for analysis in this study.
An additional eleven patients with metastatic RCC to bone and
three patients with metastatic prostate cancer to bone from the
University of Rochester Medical Center (URMC) underwent IHC
analysis for IMP3 of their bone metastasis at the time of surgical
stabilization for impending pathologic fracture. These patients
were not included in the original 33 patients that underwent pre-
operative abdominal CT, but were included for purposes of
Fig. 3. Differential IMP3 expression in renal cancer vs. prostate cancer bone metastasis. IHC was performed on retrieval tissues obtained from patients with metastatic RCC in
the iliac (A), sacrum (B), femur (C) and lumbar vertebra (D), and representative micrographs obtained at 200x are shown to illustrate the robust staining (brown) versus
retrieval tissue from a patient with metastatic prostate cancer in spine immunostained for IMP3 (E) and treated with the secondary antibody only (negative control, F).
Arrows indicated the strong IMP3 staining in the RCC bone metastases
C. Xie et al. / Journal of Bone Oncology 4 (2015) 69–7672assessing IMP3 expression in patients with bone metastatic dis-
ease from RCC.
2.2. CT protocol and CT data analysis
CT scanning was performed using a 16-MDCT (Siemens So-
matom Sensation 16, Germany) within 2 weeks prior to surgical
treatment. All images were acquired using a standardized renal
mass protocol that did not change during the study. The CT
(120.0 kV, 179.0 mA, W180/L40, DFOV 38.638.6 cm) protocol
used for non-contrast images by an 8-mm scanning span per ro-
tation and 5-mm intervals to cover the area of both sides of the
kidneys from lower pole to diaphragm. After the acquisition of
non-contrast images, arterial phase (40 s), nephrogenic phase
(90 s), portal phase (120 s) and excretory phase (180 s) images
were acquired, respectively, after the intravenous injection of
contrast. Nonionic Iohexol (1.5 ml/kg, concentration of 300 mg/
ml)-injection was employed using power injector (3.0 ml/s) via
intermedian cubital vein for enhancement. DSA was performed
following selective renal artery catheterization using 10–15 ml
Iohexol (300 mg/ml) @ (5–7 ml/s). Images were routinely obtainedin an anterior–posterior projection for both early arterial phase
and late arterial phase. (Fig. 1).
Regions of interest (ROI) for transverses CT images were
manually drawn around the margins of the entire renal mass on
multiple slices in the arterial/corticomedullary phase that excluded
fat and gas areas [18,19] to measure Hounsﬁeld attenuation values:
1) contrast enhancement within the tumor, 2) non-enhanced areas
within the tumor, 3) the contralateral normal kidney; and 4) the
abdominal aorta. The degree of tumor enhancement during the
arterial/corticomedullary phase was calculated from an appro-
priately selected similar-sized region of interest (ROI): Tumor en-
hancement in Houndsﬁeld Units (HU)¼ arterial/corticomedullary
phase HU–baseline HU (pre-contrast portion of scan). Based on the
enhancement data from Dr. Raman in Johns Hopkins University and
others [18–21], the degree of tumor contrast enhancement was
grouped as: Lowo20 HU; Intermediate 20–40 HU; and High440
HU. To assess tumor vascularity from the CT data, we performed
volumetric rendering studies with Amira
s
software (Amira
s
V5.4.0,
Visualization Sciences Group, Burlington MA). Once the kidney and
tumor volumes were generated, the Amira
s
software was used to
deﬁne the vascular and non-vascular components of the tumor by
Table 1
Clinical characteristics of the patient population who were included in the study.
Dynamic CT enhancement
scanning
Patient 72
Male 38(52.8%)
Female 34(47.2%)
Age (year) 53.1714.7
20–40 11(15.2%)
41–60 36(50.0%)
460 25(34.7%)
Clinical manifestations
Hematuria 35(48.6%)
Pain 26(36.1%)
Abdomen mass 7(9.7%)
Renal palpable mass 5(6.9%)
No clinical symptoms at 1st visit 12(16.7%)
Surgery ﬁnding
Right kidney 33(45.8%)
Left kidney 39(54.2%)
Single lesion 70(97.2%)
Upper pole 33(45.8%)
Pathological classiﬁcation [30]
Clear cell RCC 55(76.4%)
Multilocular clear cell renal cell carcinoma 5(6.9%)
Spindle cell carcinoma 5(6.9%)
Renal cell carcinoma, unclassiﬁed 4(5.6%)
Papillary transitional cell 3(4.2%)
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amples of tumors determined to have low, intermediate and high
enhancement as determined by this method.
2.3. Histology and immunohistochemistry
Hematoxylin and eosin (H&E) stained histology was performed
on demineralized parafﬁn embedded tissue as previously de-
scribed [22], and IHC was performed on parallel sections using a
mouse anti-human IMP3 primary antibody (clone 69.1, Dako,
Carpinteria, CA, USA), and a vectastain biotinylated universal sec-
ondary antibody (Dako, Carpinteria, CA, USA). Fig. 2 D–F illustrates
representative tumors with Low, Intermediate and High IMP3
expression determined by this IHC method, with blinded semi-
quantitative analysis as previously described [23]. All histological
images were obtained using Axioskop 40 microscopy (Carl Zeiss
AG, Goettingen, Germany) and Spot TR3TM image system (V
4.5.9.9, Spot Image Solutions Inc., Michigan).
2.4. Cell culture, microarray and real time RT-PCR
786-O cells obtained from Dr. G. Wu [24] and PC3 cells from
Dr. J. Lieberman were cultured in 37 °C, 5%CO2 as described pre-
vious [13]. Total RNA was isolated using RNeasy mini puriﬁcation
kit (Qiagen 74104). Microarry was performed using Affymetrix
GeneChip Human Genome U133 Plus 2.0 Array (Chip Lot
#LE23BK05) (Supplementary Table 1). Real time RT-PCR was per-
formed using Bio-Rad iScript TM cDNA synthesis Kit (Bio-Rad170-
8842), and iQTM SYBR
s
Green supermix, and ΔCt was normalized
to gapdh.
2.5. Statistical analysis
All statistical analysis was performed using Prism statistical
package Version 4.0 (GraphPad, San Diego, CA) with p
Valueso0.05 being considered statistically signiﬁcant. A one-wayanalysis of variance (ANOVA) or Newman–Keuls multiple com-
parison test was utilized for volumetric enhancement data, PCR
gene expression and microchip gene array expression analysis. A
Fischer's exact test was used to determine statistical signiﬁcance
for the semiquatitative analysis of IHC for IMP3 and its correlation
to tumor vascularity based on CT. Using the raw data, average and
standard deviation HUs were calculated for the weak, inter-
mediate and strong IMP3 expression levels. Students T-test was
performed comparing means between the three groups as well for
this data. Statistical signiﬁcance is indicated in the artwork as well
as captions of all the Figures.3. Results
We performed immunohistochemistry for IMP3 on RCC and PC
retrieval tissues from patients with bone metastases (Fig. 3). All of
the 11 RCC bone metastases samples tested were highly positive
(þþþ) for IMP3, while the non-neoplastic cells within the tumor
parenchyma did not showed immunostaining for IMP3 (Fig. 3A–
D). In comparison, the 3 PC bone metastases samples all had low
(þ) levels of IMP3 immunostaining (Fig. 3E).
To directly evaluate the IMP3 as a biomarker of RCC vascularity,
we completed a retrospective analysis of 72 patients from ZMU
who underwent contrast enhanced CT preoperatively. Table 1
provides a summary of patient characteristics for these 72 pa-
tients, including clinical manifestations and pathologic classiﬁca-
tion. As expected, the most common histologic type of RCC was
clear cell (76.4%) and 97.2% were a single lesion. The 33 patients
included in the IHC analysis had similar characteristics to the 72
patients as a whole. Fig. 1A and B and 1C–E shows images from a
representative patient with low contrast uptake and high contrast
uptake on CT respectively and subsequent DSA conﬁrming the
presence of large tumor feeding vessels in the high contrast up-
take tumors, which were not seen in the low contrast uptake tu-
mors. In order to assess the relationships between RCC primary
tumor radiological characteristics and molecular markers, we ﬁrst
quantiﬁed the CT data to determine the volumes of the kidney,
tumor and vascular vs. non-vascular regions of the tumor (Fig. 4).
Interestingly, we found that the tumors with Intermediate en-
hancement (20–40 HU) were 2-fold larger than Low and High
enhancing tumors, and that this increase in tumor size was sig-
niﬁcant in both vascular and non-vascular regions (Fig. 4B).
Moreover, the volume of the Intermediate enhancing RCC ac-
counted for 70% of the kidney volume, while the Low and High
enhancing tumors accounted for only 40% and 30% of kidney
volume respectively (Fig. 4C). Further group analysis revealed that
the High enhancing tumors were 90% vascular, which was sig-
niﬁcantly greater than the 70% vascularity observed in Inter-
mediate tumors, which was signiﬁcantly greater than the 30%
vascularity of the Low enhancement RCC (Fig. 4C). However, in-
dividual tumor volume did not correlate with tumor vascularity
(data not shown). Finally, we directly compared the vascularity of
the primary RCC tumors determined by CT to their IMP3 expres-
sion (Fig. 3D). The results demonstrated a signiﬁcant correlation
between HU and IMP3 immunostaining of the tumors.4. Discussion
Metastatic RCC is a fatal disease with survival often measured
in months, rather than years. Surgery alone is the standard of care
for patients who present with isolated renal disease at the time of
diagnosis. However, approximately 1/3 of these patients will go on
to develop clinically detectable metastatic disease, which is then
treated with systemic therapies that have been shown to prolong
Vascular 
Kidney
Nonvascular
Fig. 4. Use of volumetric contrast-enhance CT to correlate primary RCC vascularity with IMP3 expression in the tumor. Amira 3-D visualization software was employed to
quantify primary RCC tumor lesion volume within the kidney based on the anatomic structure of the contrast-enhanced CT attenuation obtained from the clinical radiology.
(A) A cartoon illustration of the manual contouring of the tumor mass (pink) from the residue normal kidney (blue) tissue and non-enhanced tissue (green) within tumor is
shown it illustrate the 2-D area measurements derived from the original CT section (A1). These 2-D measurements were then reconstructed in 3-D to derive volumes (A2),
and were also used to visualize a sagittal section (A3). Using these manipulations of the CT, the kidney, tumor and vascular/nonvascular tumor volumes were determined (B).
Of note is that neither tumor size nor vascular tumor volume corresponded to gross lesion enhancement attenuation, as deﬁned by Low (black bars), Intermediate (white
bars) and High (gray bars) HU described in Fig. 2. However, as predicted, the vascular:tumor ratio signiﬁcantly corresponded with the gross lesion enhancement attenuation
(C). Direct semiquantitative assessment of tumor vascularity (CT enhancement) vs. IMP3 expression (IHC) as described in Fig. 2 was performed on 33 tumors in this study (D),
which demonstrated a signiﬁcant correlation (* po0.05 vs. Low; ** po0.001 vs. Low; # po0.05 vs. Intermediate; ## po0.001 vs. þ)
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subset of patients who are at high risk for developing metastatic
disease could accurately be determined, systemic therapy could be
initiated at the time of diagnosis with the goal of targeting the
clinically undetectable micro-metastatic disease. Ultimately, as
targeted systemic therapies continue to improve, this could en-
hance long-term overall survival in this population of patients.
To the end of identifying novel molecular targets to diagnose
and treat RCC, our microarray studies identiﬁed IMP3 (Supple-
mentary Table 1). IMP3 is a cytosolic protein that binds mRNA, and
targets speciﬁc transcripts for processing within the cell. Although
ﬁrst identiﬁed as having high binding afﬁnity for igf2 mRNA, IMP3
also binds to many different mRNAs within the cell, and thereby
inﬂuences gene expression, including genes involved in cellular
migration and proliferation [16]. Interestingly, IMP3 is generally
not expressed in normal adult tissues, but has been found to be
present in several malignancies to varying degrees including RCC
[16,26]. Thus, it has potential as a molecular diagnostic and tar-
geted therapy if its role is determined to be essential for cancer
progression. Consistent with this thinking, several prior studieshave shown that IMP3 expression is correlated with a poorer
prognosis in patients with RCC [14,26]. Therefore, we aimed to
assess the relationship between IMP expression, RCC metastatic
potential and RCC vascularity as determined by contrast enhanced
CT.
RCC is generally considered to be a vascular tumor both at the
primary site and at the sites of metastasis, and its vascularity has
been strongly implicated in the tumor’s pathogenesis and invasive
potential. Based on our initial investigations using microarray
analysis and review of the current literature, we found that the
IMP family of proteins may be implicated in RCC tumor virulence,
and possibly vascular growth and development within the tumor.
Further analysis by real-time RT-PCR (Supplementary Fig. 1) con-
ﬁrmed that IMP3 is highly expressed in RCC, and prompted further
study of this protein and its role in the vascularity and metastatic
potential of RCC.
Several studies have been performed by other groups that in-
dicate the possibility of discriminating renal cell carcinoma sub-
types using texture analysis or single phase corticomedullary
contrast-enhanced CT [18–21]. These studies also found that CT
C. Xie et al. / Journal of Bone Oncology 4 (2015) 69–76 75contrast enhancement was a valid method of representing tumor
vascularity in either hetero- or homogeneously contrast-enhanced
lesions. In order to directly assess the relationship between IMP3
expression in primary RCC and tumor vascularity, we ﬁrst had to
develop a quantitative outcome measure of tumor vascularity
in vivo (Figs. 2 and 4A). Although several approaches to quantify
tumor vascularity have been described, a consensus on the best
method has not emerged [27]. As we were restricted to protocols
that utilize clinical CT scans, we chose a method similar to that
which we have described for other clinical conditions [28,29], but
acknowledge that this approach still requires formal prospective
studies for validation. Nevertheless, we ﬁnd our contrast CT ap-
proach to be safe, feasible and readily translatable if future studies
can validate its sensitivity and speciﬁcity.
One surprising result from our CT study was the lack of cor-
relation between primary RCC tumor size and its vascularity. While
the Low contrast enhancing tumors were 2-fold smaller than the
Intermediate enhancing tumors as expected, the High contrast en-
hancing tumors were also signiﬁcantly smaller than the Inter-
mediate tumors (Fig. 4). Holding to the theory that RCC tumor
vascularity is associated with virulence, our interpretation of this
ﬁnding is that High contrast enhancing primary RCC tumors greater
than 200 cm3 are incompatible with human life, and thus none
were observed in our study. However, consistent with the central
hypothesis of this study, we found a strong association between
primary RCC vascularity as measured by CT and IMP3 expression
(Fig. 4D). Furthermore, IHC assessment of tissue from 11 patients
with conﬁrmed metastatic RCC to bone revealed that all of the
metastatic tumors had strong IMP3 staining (Fig. 3). In contrast, we
did not see strong IHC staining in poorly vascular metastatic bone-
prostate cancer biopsies. Although our conclusions are limited by
the small sample size, these ﬁndings suggest that IMP3 may play a
critical role in tumor vascular development and potential to spread.
In summary, IMP3 is a protein that warrants further study to
assess its role in the pathogenesis of metastatic RCC. Based on our
ﬁndings, it may play a role in the vascular development of the
tumor. We conﬁrmed that contrast CT is a useful modality for
detecting tumors that will have high IMP3 staining and can
therefore be used as a relatively inexpensive and rapid method for
assessing both vascularity and probability of high IMP3 expression.
Moving forward, it will be useful to determine if CT and IMP3 can
accurately predict risk of metastatic disease to other organs and to
the bone in patients with primary RCC.Acknowledgments
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